Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Operating Leases (2019 - 2025)

Historic Operating Leases for Fortress Biotech (FBIO) over the last 7 years, with Q3 2025 value amounting to $12.8 million.

  • Fortress Biotech's Operating Leases fell 1652.5% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 1652.5%. This contributed to the annual value of $14.8 million for FY2024, which is 1931.95% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Operating Leases is $12.8 million, which was down 1652.5% from $13.3 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Operating Leases peaked at $23.7 million during Q3 2022, and registered a low of $12.8 million during Q3 2025.
  • Over the past 5 years, Fortress Biotech's median Operating Leases value was $19.5 million (recorded in 2023), while the average stood at $18.8 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 1509.24% in 2023, then tumbled by 2515.61% in 2024.
  • Quarter analysis of 5 years shows Fortress Biotech's Operating Leases stood at $21.0 million in 2021, then rose by 2.79% to $21.6 million in 2022, then fell by 15.25% to $18.3 million in 2023, then dropped by 19.32% to $14.8 million in 2024, then dropped by 13.46% to $12.8 million in 2025.
  • Its Operating Leases stands at $12.8 million for Q3 2025, versus $13.3 million for Q2 2025 and $13.8 million for Q1 2025.